Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?
Article
Dr. Karen Kelly of University of California, Davis, presents her current view on using molecular markers in early stage non-small cell lung cancer and explains the RADIANT study that she leads.
[powerpress]